Forward P/S Multiple: Artivion (AORT)

Artivion, Inc. - graphic logo of issuer AORT

Artivion, Inc. (AORT) focuses on the production of vascular adhesives and bioprostheses, leveraging global distribution to mitigate regional risks. Demand for cardiac surgery remains independent of economic conditions, ensuring business stability. The forward P/S valuation reflects market expectations, where 1.90 represents the current level of the metric. Growth prospects are supported by the implementation of robotic spraying and automated tissue cryopreservation.

artivion.com - AORT Market Cap to Projected Revenue (period 07/04/2022 - 11/17/2026)

Summary analytical data breakdowns for Artivion, Inc. (AORT)

- market price and analyst price targets:
- company stock exchange capitalization indicators:
Fundamental company analysis:AORT (Artivion Inc)
Product sample of Artivion Corp

To minimize risks when building a position, it is essential to analyze the ratio of market value to projected sales, which allows for an assessment of the premium paid for future revenue growth. This forward price-to-sales ratio reflects the resilience of the Artivion, Inc. (AORT) business model, where high loyalty among cardiac surgeons and stringent FDA regulatory barriers ensure predictable cash flows and the company's fundamental strength.

Who Artivion, Inc. competes with

Forward P/S Multiple BSX (bostonscientific.com)|EW: Market Cap to Projected Revenue|ResMed - Forward P/S Multiple|Market Cap to Future Revenue Ratio Insulet Corporation|ZBH: Forward P/S Multiple|COO - Market Cap to Expected Sales Ratio|ALGN (Align Corp) - Forward P/S Multiple|Globus Medical Corp (GMED) - Market Cap to Expected Sales Ratio|Forward P/S Multiple TMDX|Forward Price-to-Revenue Multiple Alphatec Holdings, Inc. ATEC|Forward P/S Multiple ENOV (enovis.com)|Forward P/S Multiple Integra LifeSciences Corp IART|ESTA - Price-to-Projected Revenue Ratio|BBNX: Price-to-Projected Revenue Ratio|IRMD (IRADIMED CORPORATION) - Forward Price-to-Revenue Multiple|Embecta Corp. - Forward Price to Sales|TNDM (Tandem Corp) - Forward P/S Multiple|Market Cap to Future Revenue Ratio AxoGen Inc AXGN|Price-to-Projected Revenue Ratio SI-BONE Inc (SIBN)|Orthofix Medical Inc. (OFIX) - Projected Price to Revenue|Forward P/S Multiple BVS (bioventus.com)|Forward P/S Multiple OrthoPediatrics Inc. KIDS|Treace Medical Concepts Inc - Forward P/S Multiple|Market Cap to Expected Sales Ratio Blade Air Mobility SRTA|Carlsmed (CARL) - Price-to-Projected Revenue Ratio|Future Price to Revenue RXST (RxSight Ophthalmic)|Price-to-Projected Revenue Ratio clearpointneuro.com|Forward Price-to-Revenue Multiple Stereotaxis, Inc. (STXS)|Forward P/S Multiple STIM|SGHT - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Orchestra BioMed, Inc. OBIO|ANIK: Market Cap to Projected Revenue|NSPR: Forward Price-to-Revenue Multiple|Jin Medical - Price to Expected Revenue Ratio|VANI (Vivani Medical Inc) - Forward Price-to-Revenue Multiple|Market Cap to Projected Revenue XTNT|NMTC (n1mtc.com) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Modular Medical MODD|Price-to-Projected Revenue Ratio myomo.com (MYO)|Price-to-Projected Revenue Ratio COCH (envoymedical.com)|Price-to-Projected Revenue Ratio Vivos Therapeutics Inc VVOS|enVVeno Medical Corp. - Price-to-Projected Revenue Ratio|SINT: Forward Price-to-Revenue Multiple|TNON (Tenon Medical, Inc.) - Market Cap to Projected Revenue|Lifeward Ltd. (LFWD) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Autonomix (AMIX)|Price-to-Projected Revenue Ratio INVO Fertility|Bone Biologics Corp. (BBLG) - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple AXNX (Axonics Modulation Technologies)|BIOL (Biolase, Inc.) - Forward Price to Sales|Forward P/S Multiple DYNT (dynatronics.com)|Forward Price to Sales FNA|INVO Bioscience - Forward P/S Multiple